Insider Transactions
| Date | Name | Title | Type | Filing | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Dec 02, 2008 | Chief Operating Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 20,098 | -- | -- | |
| Dec 03, 2008 | Director | Open market or private sale of non-derivative or derivative security | Form 4 | 24 | $8.50 | 1,657,121 | |
| Dec 03, 2008 | Director | Open market or private sale of non-derivative or derivative security | Form 4 | 1 | $8.50 | 61,877 | |
| Dec 08, 2008 | Director | Open market or private sale of non-derivative or derivative security | Form 4 | 2,892 | $8.54 | 1,654,229 | |
| Dec 08, 2008 | Director | Open market or private sale of non-derivative or derivative security | Form 4 | 108 | $8.54 | 61,769 | |
| Jan 02, 2009 | Chief Financial Officer | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Form 4 | 220 | $8.00 | 34,055 | |
| Jan 08, 2009 | Senior VP, Drug Development | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 4,924 | $0.64 | 54,040 | |
| Jan 08, 2009 | Senior VP, Drug Development | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 4,924 | -- | -- | |
| Feb 01, 2009 | Chief Financial Officer | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Form 4 | 220 | $8.69 | 33,835 | |
| Feb 03, 2009 | Director | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 30,000 | -- | 30,000 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.